Form 4: Repare Therapeutics EVP Michael Zinda Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Michael Zinda, EVP and Chief Scientific Officer of Repare Therapeutics, sold 5,611 common shares to cover tax obligations related to vesting restricted stock units.
Summary
- Michael Zinda, the EVP and Chief Scientific Officer of Repare Therapeutics Inc. (RPTX), sold 5,611 common shares on March 12, 2025.
- The shares were sold at a price of $1.14 per share.
- The sale was to satisfy tax withholding obligations related to the vesting and settlement of restricted stock units.
- Following the transaction, Zinda directly owns 80,297 common shares of Repare Therapeutics Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral as the transaction is related to tax obligations and not a discretionary sale, suggesting no strong positive or negative view from the executive.
Industry Context
Sales of shares to cover tax obligations upon vesting of restricted stock units are a common practice among corporate executives and are not necessarily indicative of a negative outlook on the company's future.
Stakeholder Impact
- The sale of shares may have a minor impact on shareholders due to the small volume of shares sold.
Key Dates
| Date | Description |
|---|---|
| 03/12/2025 | Date of transaction: Michael Zinda sold 5,611 common shares. |
| 03/14/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.